Improved methods for producing outer membrane vesicles in Gram-negative bacteria

Research in Microbiology
Thomas HenryR Lloubès

Abstract

Outer membrane vesicle formation occurs during Gram-negative bacterial growth. However, natural production of large amounts of outer membrane vesicles has only been described in a few bacterial genera. The purified vesicles of some bacterial pathogens have shown potential applications in vaccinology and in antibiotic therapy. This study focused on the development of a gene expression system able to induce production of large amounts of outer membrane vesicles. The Tol-Pal system of Escherichia coli, required to maintain outer membrane integrity, is composed of five cell envelope proteins, TolA, TolB, TolQ, TolR and Pal. Tol proteins are parasitized by filamentous bacteriophages and by colicins. The phage infection process and colicin import require, respectively, the N-terminal domain of the minor coat g3p protein and the translocation domain of colicins, with both domains interacting with Tol proteins. In this study, we show that the periplasmic production of either Tol, g3p or colicin domains was able to specifically destabilize the E. coli or Shigella flexneri cell envelope and to induce production of high amounts of vesicles. This technique was further found to work efficiently in Salmonella enterica serovar Typhimurium.

References

Apr 5, 2002·Microbiology·M Graciela PucciarelliFrancisco García-del Portillo

❮ Previous
Next ❯

Citations

Sep 10, 2010·Annual Review of Microbiology·Adam Kulp, Meta J Kuehn
Mar 30, 2005·Journal of Virology·Rimantas DaugelaviciusDennis H Bamford
Mar 10, 2007·Microbiology and Molecular Biology Reviews : MMBR·Eric CascalesDanièle Cavard
Feb 16, 2010·Journal of Bacteriology·Raquel M MartinezRonald K Taylor
Jun 16, 2012·PloS One·Francesco Berlanda ScorzaChristiane Gerke
Feb 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·C Preston MoonKaren G Fleming
Sep 1, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Yingyu LiuQigai He
Apr 19, 2008·Mass Spectrometry Reviews·Eun-Young LeeYong Song Gho
Mar 29, 2014·Current Opinion in Biotechnology·Jenny L BakerMatthew P DeLisa
Sep 16, 2015·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Karen G Fleming
Nov 28, 2012·Biochemical Society Transactions·Roland LloubèsDenis Duché
Oct 1, 2015·Advances in Colloid and Interface Science·Masanori ToyofukuNobuhiko Nomura
Jan 3, 2014·Journal of Proteomics·Kyoung-Soon JangWilliam M Clemons
Jul 20, 2017·Journal of Medical Microbiology·Yadira PastorCarlos Gamazo
Jul 26, 2017·Experimental Biology and Medicine·Ji-Woong ChoiHeon-Jin Lee
Jun 10, 2010·FEMS Immunology and Medical Microbiology·Nivedita RoyHemanta Koley
Sep 24, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eun-Chong HanHeon-Jin Lee
Aug 18, 2020·Applied and Environmental Microbiology·Kotaro TakakiYosuke Tashiro
Feb 23, 2021·Frontiers in Microbiology·Melanie D BalhuizenHenk P Haagsman
Mar 7, 2021·Vaccines·Akosiererem S SokariboAaron P White
Nov 1, 2005·EcoSal Plus·Amanda J McBroom, Meta J Kuehn
Mar 23, 2007·Journal of the American Chemical Society·Daniel A BonsorColin Kleanthous

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.